Cargando…
Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen
BACKGROUND: Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204294/ https://www.ncbi.nlm.nih.gov/pubmed/32375658 http://dx.doi.org/10.1186/s12879-020-05053-z |
_version_ | 1783530034889228288 |
---|---|
author | Darko, Samuel Nkansah Hanson, Henry Twumasi-Ankrah, Sampson Baffour-Awuah, Sandra Adjei-Kusi, Priscilla Yar, Denis Owusu-Dabo, Ellis |
author_facet | Darko, Samuel Nkansah Hanson, Henry Twumasi-Ankrah, Sampson Baffour-Awuah, Sandra Adjei-Kusi, Priscilla Yar, Denis Owusu-Dabo, Ellis |
author_sort | Darko, Samuel Nkansah |
collection | PubMed |
description | BACKGROUND: Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of three monthly doses of 60 mg/kg/day PZQ on schistosome egg count, liver and renal function during the treatment of urinary schistosomiasis in Ghana. METHODS: A nested case-control study was designed from a cohort screened for schistosomiasis; 28 schistosomiasis positive cases by microscopy matched with 53 healthy controls by age and gender. The study population was urban dwellers from the Asokwa sub-metropolitan area, Kumasi in Ghana. Participants were within the age range of 6 to 30 years. We assessed Schistosoma haematobium egg counts in urine and its associated impact on liver and renal function at baseline, treatment and post-treatment phases using serum. RESULTS: Of the 28 cases and 53 controls, 78.6% and 81.1% were males respectively. Globulin levels before treatment was higher in cases [36.7 (32.8, 40.1) vrs 30.5 (22.4, 33.8), p = 0.005] at pre-treatment but not at post-treatment [35.8 (31.2, 39.1) vrs 37.4 (29.7, 43.0), p = 0.767]. Estimated cure rate was 42.9, 46.4 and 96.4% after first, second and third dose respectively. Schistosome egg counts dropped significantly (p = 0.001) from before second dose to post-treatment. Similarly, levels of alanine aminotransferase (p = 0.001), aspartate aminotransferase (p = 0.028) and gamma glutamyl transferase (p = 0.001) significantly declined towards post-treatment. Estimated glomerular filtration rate significantly improved from before second dose to post-treatment using both the Chronic Kidney Disease Epidemiology Program (p = 0.001) and 4-variable Modification of Diet in Renal Disease (p = 0.002) equations. CONCLUSION: Treatment of urinary Schistosoma hematobium infections with a repeated high monthly dose of 60 mg/kg of praziquantel for 3 months is safe and effective. |
format | Online Article Text |
id | pubmed-7204294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72042942020-05-14 Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen Darko, Samuel Nkansah Hanson, Henry Twumasi-Ankrah, Sampson Baffour-Awuah, Sandra Adjei-Kusi, Priscilla Yar, Denis Owusu-Dabo, Ellis BMC Infect Dis Research Article BACKGROUND: Praziquantel (PZQ) is the standard treatment for Schistosomiasis in sub-Saharan Africa. However, there is evidence suggesting praziquantel treatment failure in Schistosome infections with associated potential renal impairment. The objective of this study was to determine the effect of three monthly doses of 60 mg/kg/day PZQ on schistosome egg count, liver and renal function during the treatment of urinary schistosomiasis in Ghana. METHODS: A nested case-control study was designed from a cohort screened for schistosomiasis; 28 schistosomiasis positive cases by microscopy matched with 53 healthy controls by age and gender. The study population was urban dwellers from the Asokwa sub-metropolitan area, Kumasi in Ghana. Participants were within the age range of 6 to 30 years. We assessed Schistosoma haematobium egg counts in urine and its associated impact on liver and renal function at baseline, treatment and post-treatment phases using serum. RESULTS: Of the 28 cases and 53 controls, 78.6% and 81.1% were males respectively. Globulin levels before treatment was higher in cases [36.7 (32.8, 40.1) vrs 30.5 (22.4, 33.8), p = 0.005] at pre-treatment but not at post-treatment [35.8 (31.2, 39.1) vrs 37.4 (29.7, 43.0), p = 0.767]. Estimated cure rate was 42.9, 46.4 and 96.4% after first, second and third dose respectively. Schistosome egg counts dropped significantly (p = 0.001) from before second dose to post-treatment. Similarly, levels of alanine aminotransferase (p = 0.001), aspartate aminotransferase (p = 0.028) and gamma glutamyl transferase (p = 0.001) significantly declined towards post-treatment. Estimated glomerular filtration rate significantly improved from before second dose to post-treatment using both the Chronic Kidney Disease Epidemiology Program (p = 0.001) and 4-variable Modification of Diet in Renal Disease (p = 0.002) equations. CONCLUSION: Treatment of urinary Schistosoma hematobium infections with a repeated high monthly dose of 60 mg/kg of praziquantel for 3 months is safe and effective. BioMed Central 2020-05-06 /pmc/articles/PMC7204294/ /pubmed/32375658 http://dx.doi.org/10.1186/s12879-020-05053-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Darko, Samuel Nkansah Hanson, Henry Twumasi-Ankrah, Sampson Baffour-Awuah, Sandra Adjei-Kusi, Priscilla Yar, Denis Owusu-Dabo, Ellis Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen |
title | Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen |
title_full | Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen |
title_fullStr | Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen |
title_full_unstemmed | Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen |
title_short | Three monthly doses of 60 mg/kg praziquantel for Schistosoma haematobium infection is a safe and effective treatment regimen |
title_sort | three monthly doses of 60 mg/kg praziquantel for schistosoma haematobium infection is a safe and effective treatment regimen |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204294/ https://www.ncbi.nlm.nih.gov/pubmed/32375658 http://dx.doi.org/10.1186/s12879-020-05053-z |
work_keys_str_mv | AT darkosamuelnkansah threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen AT hansonhenry threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen AT twumasiankrahsampson threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen AT baffourawuahsandra threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen AT adjeikusipriscilla threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen AT yardenis threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen AT owusudaboellis threemonthlydosesof60mgkgpraziquantelforschistosomahaematobiuminfectionisasafeandeffectivetreatmentregimen |